NCT05229601 - A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

May 30, 2024

Study Completion Date

May 30, 2024

Conditions

Soft Tissue SarcomaRenal Cell CarcinomaUterine CarcinosarcomaHepatocellular CarcinomaHead and Neck Squamous Cell CarcinomaMelanoma

Interventions

DRUG

HFB301001

"Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively.~Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation."

Trial Locations (10)

21201

University of Maryland, Baltimore

22031

NEXT Virginia Cancer Specialists, Fairfax

28041

Hospital Universitario 12 de Octubre, Madrid

32224

Mayo Clinic, Jacksonville

46010

Hospital Clinico Universitario de Valencia, Valencia

55905

Mayo Clinic, Rochester

85259

Mayo Clinic, Scottsdale

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

02215

Dana Farber Cancer Institute, Boston

08035

Hospital Universitario Vall d'Hebron, Barcelona